Arcus Biosciences (RCUS) Free Cash Flow (2017 - 2026)
Arcus Biosciences (RCUS) posted quarterly Free Cash Flow of -$138.0 million for Q1 2026, down 3.76% year-over-year from -$143.4 million in Q1 2025, and down 14.05% quarter-over-quarter from -$121.0 million in Q4 2025.
Powered by 
Analysis
Arcus Biosciences (RCUS) Free Cash Flow (2017 - 2026) Analysis & Trends
Arcus Biosciences' Free Cash Flow history runs 10 years deep, the most recent figure standing at -$138.0 million for Q1 2026.
- In Q1 2026, Free Cash Flow fell 3.76% year-over-year to -$138.0 million; the TTM figure through Mar 2026 stood at -$489.0 million (down 75.9% YoY), while the FY2025 annual figure was -$484.0 million, down 227.03% from the prior year.
- Free Cash Flow for Q1 2026 stood at -$138.0 million, down from -$121.0 million in the prior quarter.
- The five-year high for Free Cash Flow was $651.0 million in Q1 2022, with the low at -$138.0 million in Q1 2026.
- The 5-year median for Free Cash Flow is -$94.0 million (2024), against an average of -$39.3 million.
- The sharpest annual moves came in 2022 and 2025: Free Cash Flow soared 1042.11% in 2022, then plunged 4333.33% in 2025.
- Arcus Biosciences' Free Cash Flow stood at -$72.0 million in 2022, then slumped by 38.89% to -$100.0 million in 2023, then climbed by 6.0% to -$94.0 million in 2024, then declined by 28.72% to -$121.0 million in 2025, then fell by 14.05% to -$138.0 million in 2026.
- Business Quant data shows RCUS's Free Cash Flow at -$138.0 million in Q1 2026, -$121.0 million in Q4 2025, and -$97.0 million in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 1.01 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 572.80 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -563.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | -389.61 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 437.80 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 292.04 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 477.44 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -95.09 Mn |
| 10 | Arcus Biosciences | 3.74 Bn | 3.04 Bn | - | -119.00 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -119.00 Mn |
| Mar 31, 2026 | -141.00 Mn |
| Dec 31, 2025 | -120.00 Mn |
| Sep 30, 2025 | -91.00 Mn |
| Jun 30, 2025 | -133.00 Mn |
| Mar 31, 2025 | -133.00 Mn |
| Dec 31, 2024 | -94.00 Mn |
| Sep 30, 2024 | 27.00 Mn |
| Jun 30, 2024 | -84.00 Mn |
| Mar 31, 2024 | 3.00 Mn |
| Dec 31, 2023 | -94.00 Mn |
| Sep 30, 2023 | -73.00 Mn |
| Jun 30, 2023 | -57.00 Mn |
| Mar 31, 2023 | -106.00 Mn |
| Dec 31, 2022 | -70.00 Mn |
| Sep 30, 2022 | -83.00 Mn |
| Jun 30, 2022 | -62.00 Mn |
| Mar 31, 2022 | 647.00 Mn |
| Dec 31, 2021 | -70.36 Mn |
| Sep 30, 2021 | -61.62 Mn |